查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1862582

药物发现资讯学市场按组件、应用、部署类型、最终用户和治疗领域划分－2025-2032年全球预测

Drug Discovery Informatics Market by Component, Application, Deployment, End User, Therapeutic Area - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，药物发现资讯学市场将成长至 69.5 亿美元，复合年增长率为 10.20%。

关键市场统计数据
基准年 2024 31.9亿美元
预计年份：2025年 35.1亿美元
预测年份 2032 69.5亿美元
复合年增长率 (%) 10.20%

药物发现资讯学发展架构以及组织为整合运算平台和服务所应采取的策略重点

药物发现资讯学融合了计算科学、生物学和转化研究，彻底改变了治疗假设的生成、检验和推进方式。生物资讯学和化学资讯学的创新拓展了In Silico方法的范围和精确度，使研究团队能够以前所未有的深度探索基因组、蛋白质组和化学空间。此外，相关服务能够将平台输出转换为可部署的工作流程，并透过咨询、系统整合和持续支持，确保模型输出与实验室执行之间的无缝衔接。

识别技术、服务和管治的融合趋势，这些趋势将重塑药物发现资讯学和整个研究生态系统的伙伴关係模式。

由于调查方法日趋成熟、平台整合以及云端原生运算范式的普及，药物发现资讯学领域正在经历变革。基于多组体学资料集训练的机器学习模型如今已常规与基于物理的模拟相结合，分子对接、QSAR建模和虚拟筛检方法的通量和预测精度也在不断提高。这些技术进步得益于对可重复性和可解释性的日益重视，促使供应商和研究团队加强对溯源管理、模型检验框架和透明性能基准的投入。

评估2025年关税相关贸易变化对药物研发专案中供应商多元化、合约创新和策略布局选择的影响

2025年美国关税环境的调整带来了一层商业性不确定性，这种不确定性波及采购、供应商策略和国际合作。在硬体、专用运算设备和某些软体相关服务与跨境贸易密切相关的领域，关税正促使各组织重新评估筹资策略和总成本。事实上，采购团队正在扩大供应商范围，纳入国内供应商和区域合作伙伴，一些组织还在协商签订多年期合同，以应对关税的进一步波动。

分析组件、应用、部署、最终用户和治疗领域细分，以识别差异化的部署模式和策略机会领域。

细分市场分析阐明了不同组件、应用、部署模式、最终用户和治疗领域的产能和需求分布情况，揭示了差异化的部署模式和能力缺口。按组件划分，市场由「服务」和「软体」两部分组成。服务包括咨询、系统整合和支援/维护能力，这些能力弥合了平台功能与实验室操作之间的差距；而软体则细分为生物资讯学和化学资讯学。在生物资讯学领域，基因组资讯学、蛋白质组学和转录组学分别反映了不同的数据模式和分析需求。在化学资讯学领域，分子对接、QSAR建模和虚拟筛检代表了支援化合物优先排序和虚拟先导化合物发现的融合方法。

绘製区域管理体制、人才集中度和基础设施现状如何影响全球扩张选择、伙伴关係和合作模式的图谱

区域趋势正在影响各组织部署资讯解决方案和建构伙伴关係的方式，每个区域都呈现不同的监管环境、人才储备和基础设施考量。在美洲，对转化研究的大力投入、生物製药总部的高度集中以及成熟的云端运算和高效能运算 (HPC) 能力，共同促进了整合生物资讯学和化学资讯学平台的快速普及。这种环境支持学术界和商业伙伴之间的复杂合作，强调互通性和能够支持跨机构端到端药物发现工作流程的供应商生态系统。

分析平台供应商、整合商、服务供应商和研究合作伙伴如何建立能力和合作伙伴关係，以提供端到端的药物发现解决方案。

药物发现资讯学领域的公司在平台开发、服务产品和整合伙伴关係方面展现出差异化的能力。成熟的软体供应商专注于建立强大且检验的生物资讯学和化学资讯学工具链，并投资于模组化架构，使客户能够整合基因组学、蛋白质组学和分子建模的输出结果。同时，越来越多的专业公司正在利用机器学习和基于物理的模型来提高ADMET预测、虚拟筛检和基于结构的药物设计的预测性能。他们通常与大规模整合商合作，将解决方案部署到工业客户。

领导者可以采取哪些切实可行的策略步骤来建立可互通的平台、平衡采用风险并加强模型管治，从而加速其药物研发进程？

产业领导者应采取一系列实际有效且影响深远的行动，使组织能力与新兴的资讯需求保持一致，并保障策略弹性。首先，应优先考虑可互通的架构和标准化的资料模型，以便在无需大规模重新设计的情况下整合新工具。这有助于减少供应商锁定，并加速跨职能工作流程。其次，应采用混合部署策略，将本地资源的安全性和可控性与云端环境的弹性运算能力和协作优势结合。这种方法允许团队将敏感资料工作流程分配到託管环境中，同时利用公共云端进行运算密集型模拟。

采用混合调查方法，结合相关人员访谈和二手分析，得出检验的研究结果和透明的限制。

本分析的调查方法结合了质性研究和来自多个资讯来源的系统性综合分析，旨在得出有效且可操作的见解。主要研究包括对製药和生物技术公司、合约研究组织 (CRO)、平台供应商和学术研究机构的关键相关人员进行访谈，重点关注采购行为、实施决策、整合挑战和治疗领域优先事项。这些访谈旨在从实践者的观点了解功能、痛点和策略权衡，受访者涵盖了计算科学家、研发总监、营运经理等多个职位。

总结了影响电脑辅助药物发现和转化研究未来的方法论、商业性和营运驱动因素。

累积分析表明，该领域正处于转型期。调查方法的进步、平台的成熟以及商业性动态的转变正在共同改变药物发现的概念和实施方式。资讯科学能力不再是辅助工具，而是支持假设生成和候选药物推进的核心要素，而软体平台和服务之间的相互作用决定了机构将计算洞察转化为实际应用的程度。受地域和关税等商业性因素驱动，对采购选择和部署架构构成实际限制。同时，按应用和治疗领域进行细分，可以明确哪些领域的投资能够带来最大的科学和营运回报。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 透过将人工智慧驱动的表型筛检资料整合到云端基础的资讯平台中，加速新型靶点的识别。
  • 引入联邦学习框架，实现临床前药物发现工作流程中机构间安全资料共用
  • 实现量子机器学习演算法，用于复杂化学库的高通量虚拟筛检
  • 应用多体学资料整合工具建构精准医疗发展预测模型
  • 利用先进的自然语言处理技术，在药物研发流程中扩展真实世界证据分析
  • 引入基于区块链的溯源追踪系统，以检验化合物并提高研究的可重复性。
  • 利用数位双胞胎模型模拟患者特异性药物反应并优化先导化合物选择

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 药物发现资讯学市场（依组件划分）

  • 服务
    • 咨询
    • 一体化
    • 支援与维护
  • 软体
    • 生物资讯学
      • 基因组资讯学
      • 蛋白质体学资讯学
      • 转录组学资讯学
    • 化学资讯学
      • 分子对接
      • QSAR建模
      • 虚拟筛检

9. 按应用分類的药物发现资讯学市场

  • ADMET预测
    • 代谢预测
    • 药物动力学预测
    • 毒性预测
  • 线索发现
    • 高通量筛检资讯学
    • 从点击量到销售线索的资讯学
    • 虚拟筛检资讯学
  • 分子建模模拟
    • 分子动力学
    • QSAR建模
    • 基于结构的设计
  • 目标识别
    • 基因组分析
    • 蛋白质体学分析
    • 目标检验资讯学

第十章：按实施类型分類的药物发现资讯学市场

  • 云
    • 混合云端
    • 私有云端
    • 公共云端
  • 本地部署
    • 客户端/伺服器
    • 企业伺服器

第十一章 以最终用户分類的药物发现资讯学市场

  • 学术研究机构
  • CRO（受託研究机构）
  • 製药和生物技术公司

第十二章 按治疗领域分類的药物发现资讯学市场

  • 循环系统疾病
  • 感染疾病
  • 代谢性疾病
  • 神经系统疾病
  • 肿瘤学

第十三章 各地区药物发现资讯学市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 药物发现资讯学市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国药物发现资讯学市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Dassault Systemes SE
    • PerkinElmer, Inc.
    • Certara, Inc.
    • Schrodinger, Inc.
    • Genedata AG
    • Dotmatics Ltd
    • TIBCO Software Inc.
    • BioSolveIT GmbH
    • Optibrium Ltd
    • Clarivate PLC
Product Code: MRR-521BAA36EBB5

The Drug Discovery Informatics Market is projected to grow by USD 6.95 billion at a CAGR of 10.20% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.19 billion
Estimated Year [2025] USD 3.51 billion
Forecast Year [2032] USD 6.95 billion
CAGR (%) 10.20%

Framing the evolution of drug discovery informatics and the strategic priorities organizations must adopt to integrate computational platforms and services

Drug discovery informatics sits at the nexus of computational science, biology, and translational research, reshaping how therapeutic hypotheses are generated, validated, and advanced. Innovations in bioinformatics and cheminformatics have expanded the scope and precision of in silico approaches, enabling research teams to interrogate genomic, proteomic, and chemical spaces with unprecedented depth. These capabilities are complemented by services that translate platform outputs into deployable workflows, with consulting, systems integration, and ongoing support ensuring continuity between model outputs and laboratory execution.

Across organizations, this convergence is driving a shift in operational models: software platforms that once served as niche tools are now integral to discovery pipelines, while service providers are embedding advanced analytics into end-to-end solutions. As a result, cross-functional teams composed of computational scientists, bench researchers, and data engineers are becoming standard, fostering rapid iteration between hypothesis generation and empirical validation. In this context, leaders must prioritize interoperability, data provenance, and lifecycle management of computational models to preserve scientific rigor while accelerating time-to-experimentation. Understanding these dynamics is essential for stakeholders seeking to align capabilities with strategic goals and to navigate the competitive landscape of platform vendors, integrators, and research institutions.

Identifying the converging technological, service, and governance trends reshaping drug discovery informatics and partnership models across the research ecosystem

The landscape of drug discovery informatics is undergoing a transformative shift driven by methodological maturation, platform integration, and the mainstreaming of cloud-native compute paradigms. Machine learning models trained on multi-omic datasets are now routinely coupled with physics-based simulations, while molecular docking, QSAR modeling, and virtual screening methods have improved in throughput and predictive value. These technical gains are reinforced by a growing emphasis on reproducibility and explainability, prompting vendors and research groups to invest in provenance, model validation frameworks, and transparent performance benchmarks.

Concurrently, services ecosystems have evolved to provide not only implementation support but also strategic advisory roles. Consulting teams increasingly help organizations assess the fit of bioinformatics and cheminformatics solutions against internal capabilities, and integration experts orchestrate data flows between laboratory information management systems, high-performance computing resources, and cloud environments. The rise of hybrid deployment options allows organizations to balance data sensitivity with scalability, enabling secure on-premise processing for protected datasets and public cloud bursts for compute-intensive simulations. Taken together, these developments are reshaping partnership models between technology providers, contract research organizations, and end users, creating new pathways for innovation while raising the bar for governance and interoperability.

Assessing how tariff-related trade shifts in 2025 are prompting supplier diversification, contractual innovation, and strategic deployment choices in discovery programs

The United States tariff environment in 2025 introduced layers of commercial uncertainty that ripple across procurement, supplier strategies, and international collaborations. Where hardware, specialized computational appliances, and certain software-linked services intersect with cross-border trade, tariffs have prompted organizations to reassess sourcing strategies and total cost of engagement. In practice, procurement teams have expanded supplier panels to include domestic vendors and regional partners, and some organizations have negotiated multi-year agreements to protect against further tariff volatility.

These adjustments have implications for research timelines and capital planning. R&D leaders are increasingly evaluating the tradeoffs between acquiring on-premise infrastructure and adopting cloud-based alternatives that mitigate hardware import exposure. Similarly, partnerships with contract research organizations and platform providers are being structured to share risk, with clauses that address tariff-related cost changes and delivery contingencies. In addition, tariff-driven supply chain realignments have intensified interest in regionalized data processing and storage, both to reduce exposure and to meet evolving regulatory obligations. Ultimately, the cumulative impact of tariffs is less a single cost shock and more a stimulus for strategic supplier diversification, contractual innovation, and accelerated adoption of deployment models that decouple computational capacity from geopolitically sensitive hardware supply chains.

Unpacking component, application, deployment, end-user, and therapeutic area segmentation to reveal differentiated adoption patterns and strategic opportunity spaces

Segmentation analysis clarifies how capabilities and demand are distributed across components, applications, deployments, end users, and therapeutic areas, revealing differentiated adoption patterns and capability gaps. By component, the market comprises Services and Software; Services encompasses consulting, systems integration, and support and maintenance functions that bridge the gap between platform capabilities and laboratory operations, while Software divides into Bioinformatics and Cheminformatics. Within Bioinformatics, genomics informatics, proteomics informatics, and transcriptomics informatics reflect distinct data modalities and analytic requirements; within Cheminformatics, molecular docking, QSAR modeling, and virtual screening represent convergent methods that support compound prioritization and virtual hit discovery.

Application segmentation highlights how analytical techniques are applied: ADMET prediction spans metabolism, pharmacokinetics, and toxicity prediction workflows that inform early attrition mitigation; lead discovery combines high-throughput screening informatics, hit-to-lead processing, and virtual screening informatics to accelerate candidate selection; molecular modeling simulation includes molecular dynamics, QSAR modeling, and structure-based design used to refine candidates; and target identification blends genomic and proteomic analyses with target validation informatics to prioritize biological hypotheses. Deployment choices manifest as cloud and on-premise models; cloud offerings differentiate across hybrid cloud, private cloud, and public cloud options, while on-premise deployments range from client-server to enterprise server implementations. End users include academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies, each exhibiting unique procurement behaviors, risk tolerances, and demands for customization. Therapeutic area segmentation spans cardiovascular disease, infectious disease, metabolic disorders, neuroscience, and oncology, reflecting both scientific complexity and investment focus. Understanding these segments in an integrated manner enables targeted capability development and market-facing strategies that align technological strengths with user needs and therapeutic priorities.

Mapping how regional regulatory regimes, talent concentrations, and infrastructure realities influence deployment choices, partnerships, and collaboration models globally

Regional dynamics are shaping how organizations deploy informatics solutions and structure partnerships, with each geography presenting distinct regulatory landscapes, talent pools, and infrastructure considerations. In the Americas, strong investment in translational research, a deep concentration of biopharma headquarters, and established cloud and HPC capacity combine to favor rapid adoption of integrated bioinformatics and cheminformatics platforms. This environment supports complex collaborations between academic centers and commercial partners, and it places a premium on interoperability and vendor ecosystems that can support end-to-end discovery workflows across diverse institutions.

Europe, the Middle East, and Africa present a heterogeneous mix of regulatory regimes and research ecosystems. In parts of Europe, stringent data protection and regional research funding frameworks encourage hybrid deployment models and strong emphasis on data governance. Meanwhile, pockets of innovation across the region drive demand for localized expertise and integration services that can adapt global platforms to regional research priorities. In the Asia-Pacific region, rapid expansion of biotech activity, sizable talent pools in computational biology and chemistry, and policy initiatives that prioritize innovation have catalyzed adoption of cloud-native solutions and public-private partnerships. However, organizations in this region also emphasize cost-efficiency and scalable deployment models that can accommodate fast-growing research portfolios. Across all regions, cross-border collaborations and virtualized research networks are increasing, creating new imperatives for standardized data exchange, compliance, and secure collaboration practices.

Profiling how platform vendors, integrators, service providers, and research partners are organizing capabilities and alliances to deliver end-to-end discovery solutions

Companies operating in the drug discovery informatics space exhibit differentiated capabilities across platform development, service delivery, and integrative partnerships. Established software vendors focus on building robust, validated toolchains for bioinformatics and cheminformatics, investing in modular architectures that enable customers to combine genomic, proteomic, and molecular modeling outputs. Simultaneously, a growing cohort of specialized firms leverages machine learning and physics-informed models to enhance predictive performance in ADMET prediction, virtual screening, and structure-based design, often partnering with larger integrators to reach enterprise customers.

Service-oriented organizations, including consulting firms and systems integrators, play a pivotal role in helping end users translate platform capabilities into operational workflows. These providers are extending offerings beyond tactical implementation to include model governance, data harmonization, and continuous performance monitoring. Contract research organizations are increasingly embedding informatics capabilities into trial and preclinical workflows, while academic spinouts contribute novel algorithms and domain expertise that accelerate scientific breakthroughs. Strategic alliances between platform vendors, cloud providers, and CROs are becoming more common, enabling bundled offerings that reduce integration friction for customers. Observed across the ecosystem is an emphasis on open interfaces, standardized data models, and partnership structures that distribute risk while preserving the capacity for rapid innovation.

Practical strategic moves for leaders to build interoperable platforms, balance deployment risks, and strengthen model governance to accelerate discovery pipelines

Industry leaders should pursue a set of pragmatic, high-impact actions to align organizational capabilities with emerging informatics demands and to protect strategic flexibility. First, prioritize interoperable architectures and standardized data models so that new tools can be integrated without extensive reengineering; this reduces vendor lock-in and accelerates cross-functional workflows. Second, adopt a hybrid deployment strategy that balances the security and control of on-premise resources with the elastic compute and collaboration benefits of cloud environments. This approach allows teams to allocate sensitive data workflows to controlled environments while leveraging public cloud for compute-intensive simulations.

Third, strengthen supplier diversification and contractual mechanisms to manage geopolitical and tariff-related risks. Include clauses that address cost adjustments and delivery contingencies, and cultivate regional supplier relationships where appropriate. Fourth, invest in workforce development by combining computational training for wet-lab scientists with domain education for data engineers, building multidisciplinary teams capable of iterating rapidly between models and experiments. Fifth, establish robust model governance frameworks that encompass validation protocols, provenance tracking, and performance monitoring, ensuring reproducibility and regulatory readiness. Finally, pursue targeted partnerships with academic centers and CROs to access specialized assays and validation pathways, thereby shortening the route from in silico prediction to empirically supported candidate progression.

Explaining the mixed-method research approach that integrates stakeholder interviews and secondary analysis to produce validated insights and transparent limitations

The research methodology underpinning this analysis combined multi-source qualitative inquiry with structured synthesis to produce defensible, actionable insights. Primary research included interviews with key stakeholders across pharmaceutical and biotechnology companies, contract research organizations, platform vendors, and academic research groups, focusing on procurement behavior, deployment decisions, integration challenges, and therapeutic area priorities. These engagements were designed to capture practitioner perspectives on capabilities, pain points, and strategic tradeoffs, and interview participants represented computational scientists, R&D leaders, and operations managers.

Secondary research reviewed technical literature, vendor documentation, and publicly available case studies to contextualize practitioner testimony and to validate technical trends. Data synthesis emphasized triangulation: where multiple independent sources converged on similar findings, confidence in the insight increased. Segmentation was applied along component, application, deployment, end-user, and therapeutic area dimensions to reflect how capabilities and demand differ across use cases. Limitations of the methodology include potential selection bias in stakeholder participation and the rapid pace of technological change that can outdate specific tool-level details; to mitigate these risks, the approach prioritized thematic patterns and structural dynamics that are robust across vendors and geographies. Ethical considerations guided the research, including anonymization of interview responses and adherence to consent protocols for proprietary information.

Concluding insights that synthesize methodological, commercial, and operational drivers shaping the future of computational discovery and translational research

The cumulative analysis highlights a field in motion: methodological advances, platform maturation, and shifting commercial dynamics are converging to reshape how drug discovery is conceptualized and executed. Informatics capabilities are no longer auxiliary tools but central enablers of hypothesis generation and candidate progression, and the interplay between software platforms and services determines the degree to which organizations can operationalize computational insights. Regional and tariff-driven commercial factors introduce practical constraints that influence procurement choices and deployment architectures, while segmentation by application and therapeutic area clarifies where investments will yield the greatest scientific and operational returns.

For research leaders and commercial strategists, the imperative is clear: prioritize modular, governed informatics ecosystems that support reproducibility, integrate with laboratory operations, and scale across deployment scenarios. By aligning talent, governance, and partnership strategies with technological advances, organizations can convert computational promise into experimentally validated therapeutics. Ultimately, success hinges on the ability to maintain scientific rigor while adopting adaptive procurement and deployment practices that absorb commercial volatility and accelerate translational progress.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven phenotypic screening data into cloud-based informatics platforms to accelerate novel target identification
  • 5.2. Adoption of federated learning frameworks for secure cross-institutional data sharing in preclinical drug discovery workflows
  • 5.3. Implementation of quantum machine learning algorithms for high-throughput virtual screening of complex chemical libraries
  • 5.4. Application of multi-omics data integration tools to inform predictive models for precision therapeutic development
  • 5.5. Expansion of real-world evidence analytics in drug discovery pipelines using advanced natural language processing approaches
  • 5.6. Deployment of blockchain-enabled provenance tracking systems for chemical compound validation and research reproducibility
  • 5.7. Utilization of digital twin modeling to simulate patient-specific drug responses and optimize lead compound selection

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug Discovery Informatics Market, by Component

  • 8.1. Services
    • 8.1.1. Consulting
    • 8.1.2. Integration
    • 8.1.3. Support And Maintenance
  • 8.2. Software
    • 8.2.1. Bioinformatics
      • 8.2.1.1. Genomics Informatics
      • 8.2.1.2. Proteomics Informatics
      • 8.2.1.3. Transcriptomics Informatics
    • 8.2.2. Cheminformatics
      • 8.2.2.1. Molecular Docking
      • 8.2.2.2. Qsar Modeling
      • 8.2.2.3. Virtual Screening

9. Drug Discovery Informatics Market, by Application

  • 9.1. Admet Prediction
    • 9.1.1. Metabolism Prediction
    • 9.1.2. Pharmacokinetics Prediction
    • 9.1.3. Toxicity Prediction
  • 9.2. Lead Discovery
    • 9.2.1. High Throughput Screening Informatics
    • 9.2.2. Hit To Lead Informatics
    • 9.2.3. Virtual Screening Informatics
  • 9.3. Molecular Modeling Simulation
    • 9.3.1. Molecular Dynamics
    • 9.3.2. Qsar Modeling
    • 9.3.3. Structure Based Design
  • 9.4. Target Identification
    • 9.4.1. Genomic Analysis
    • 9.4.2. Proteomic Analysis
    • 9.4.3. Target Validation Informatics

10. Drug Discovery Informatics Market, by Deployment

  • 10.1. Cloud
    • 10.1.1. Hybrid Cloud
    • 10.1.2. Private Cloud
    • 10.1.3. Public Cloud
  • 10.2. On Premise
    • 10.2.1. Client Server
    • 10.2.2. Enterprise Server

11. Drug Discovery Informatics Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Biotechnology Companies

12. Drug Discovery Informatics Market, by Therapeutic Area

  • 12.1. Cardiovascular Diseases
  • 12.2. Infectious Diseases
  • 12.3. Metabolic Disorders
  • 12.4. Neuroscience
  • 12.5. Oncology

13. Drug Discovery Informatics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug Discovery Informatics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug Discovery Informatics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Dassault Systemes SE
    • 16.3.2. PerkinElmer, Inc.
    • 16.3.3. Certara, Inc.
    • 16.3.4. Schrodinger, Inc.
    • 16.3.5. Genedata AG
    • 16.3.6. Dotmatics Ltd
    • 16.3.7. TIBCO Software Inc.
    • 16.3.8. BioSolveIT GmbH
    • 16.3.9. Optibrium Ltd
    • 16.3.10. Clarivate PLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. DRUG DISCOVERY INFORMATICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. DRUG DISCOVERY INFORMATICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG DISCOVERY INFORMATICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONSULTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INTEGRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SUPPORT AND MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMICS INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMICS INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TRANSCRIPTOMICS INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CHEMINFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DOCKING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ADMET PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLISM PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACOKINETICS PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TOXICITY PREDICTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIGH THROUGHPUT SCREENING INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HIT TO LEAD INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY VIRTUAL SCREENING INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR MODELING SIMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY MOLECULAR DYNAMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY QSAR MODELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY STRUCTURE BASED DESIGN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY GENOMIC ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY TARGET VALIDATION INFORMATICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY DEPLOYMENT, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HYBRID CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HYBRID CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HYBRID CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HYBRID CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY HYBRID CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PRIVATE CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PRIVATE CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PRIVATE CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PRIVATE CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PRIVATE CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PUBLIC CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PUBLIC CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PUBLIC CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLIENT SERVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLIENT SERVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLIENT SERVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLIENT SERVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLIENT SERVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CLIENT SERVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ENTERPRISE SERVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ENTERPRISE SERVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ENTERPRISE SERVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ENTERPRISE SERVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ENTERPRISE SERVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ENTERPRISE SERVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SIZE, BY NEUROSCIENCE, BY REGION, 2018-2024 (USD MILLIO